|9 Months Ended|
Sep. 30, 2021
|INTANGIBLE ASSETS [Abstract]|
Intangible assets at September 30, 2021 and December 31, 2020 consist of the following:
All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets was $0.2 million for the three months ended September 30, 2021 and 2020, and $0.5 million for the nine months ended September 30, 2021 and 2020. Estimated aggregate future aggregate amortization expense is expected to be as follows:
The entire disclosure for all or part of the information related to intangible assets.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef